GET DAILY SIGNALSSenseonics Holdings (SENS): Analyst Targets Average $13 With Room for a +33% Move
Key Takeaways
- The central target of $13 is the arithmetic mean of six current, individually attributed analyst price targets reviewed for this analysis, with a low-to-high range of roughly $9 to $18.
- At the latest verified close near $9.80, reaching $13 would require a move of approximately 33%, a substantial gain but well within the span analysts already publish.
- Bullish analysts point to accelerating revenue and the internalized commercial model for the Eversense 365 continuous glucose monitoring (CGM) system; cautious analysts emphasize dilution, execution risk, and persistent losses.
- The target range is unusually wide, reflecting genuine disagreement about adoption speed and funding needs rather than a firm consensus.
- The strongest supports are triple-digit revenue growth and a near-term pipeline catalyst; the biggest risks are continued cash burn, shareholder dilution, and competition from larger CGM makers.
- You can find more detail on this company's Major News and Today's Price Move, along with a Forecast and Earnings coverage, on Tickeron's dedicated pages.
- Explore Trending AI Robots to see how AI-driven trading tools are monitoring opportunities across the market.
Breaking Down the Analyst Consensus
Senseonics Holdings, Inc. (SENS) is a commercial-stage medical technology company, not an ETF. It develops and manufactures long-term implantable continuous glucose monitoring systems under the Eversense brand, including the 365-day Eversense 365 sensor.
This analysis reviewed six current, individually attributed price targets rather than relying on a single headline figure. Mizuho (Anthony Petrone) holds a Buy rating with a $18 target, lowered from $20 in July 2026. TD Cowen (Joshua Jennings) reiterated a Buy with a $15 target in late September 2026, and H.C. Wainwright (Sean Lee) reiterated a Buy with a $14 target. Lake Street (Ben Haynor) carries a Buy at $12. On the cautious side, Barclays (Matt Miksic) initiated coverage at Equal weight with a $10 target in October 2026, and Stifel maintained a Hold with a $9 target. Averaging these six figures produces a mean of exactly $13.00, used here as the central target. The range spans about $9 to $18, underscoring wide disagreement rather than consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where SENS Stands Today and the Road to $13
The latest verified close sits near $9.80, with the shares trading in the upper portion of a 52-week range of roughly $4.79 to $10.64. Reaching the $13 central target implies an upside of roughly 33%, a substantial move that is nonetheless inside the published analyst range. The company is not yet profitable on a GAAP (generally accepted accounting principles) basis, so the stock trades largely on revenue momentum and the market's view of future adoption rather than current EPS (earnings per share). A move toward the target would most likely be driven by continued revenue acceleration, evidence that the internalized commercial model is scaling efficiently, and progress on the next-generation Gemini platform.
What Could Support a Move Toward the Target
The most important tailwind is revenue growth. For the quarter ended June 30, 2026, Senseonics reported roughly $14.5 million in revenue, more than double the prior-year period, following its transition of Eversense commercialization in-house from partner Ascensia at the start of 2026. Analysts' forward estimates point to further growth, and insider buying plus an activist investor's disclosed position have added a measure of confidence in the stock. A successful launch cadence for Eversense 365 and progress on Gemini would reinforce the bullish end of the target range.
What Could Prevent the Target From Being Reached
The principal obstacles are financial and competitive. Senseonics remains deeply unprofitable, and a roughly $80 million public offering in May 2026 weighed on the shares, highlighting dilution risk if the company needs additional capital. CGM is dominated by larger, well-funded rivals, and execution of the internalized commercial strategy is still unproven at scale. Persistent cash burn, slower-than-expected adoption, or another dilutive raise could keep the stock near the lower end of the $9-to-$18 range rather than driving it toward $13.
Technical Levels and Market Structure
The stock has been trending higher off its 52-week low near $4.79 and is approaching its 52-week high around $10.64. A decisive move above that high could clear a meaningful resistance level and put the psychological and analyst-heavy $13-to-$15 zone in focus. On the downside, the $8-to-$9 area, where Stifel's target and recent consolidation sit, represents a notable support zone. From what I see, these levels remain key for any sustained move higher.
Time Horizon and What Investors Should Monitor
Analyst price targets typically reflect a roughly 12-month research horizon, though individual assumptions differ materially across the $9-to-$18 range. Key items to watch include quarterly revenue growth and gross margin trends, updates on the Gemini platform timeline, any capital-raising announcements, analyst target revisions, and competitive developments in the broader CGM market. Insider and activist activity also bear watching given the stock's history of volatility. I’m watching this closely as the next few quarters unfold.
AI Daily Buy/Sell Signals
In my research process, Tickeron's AI Daily Buy/Sell Signals have become a useful complement to traditional analysis. These signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders use these signals to discover new opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning allows. For those tracking SENS alongside the broader market, this tool offers a way to complement fundamental research with automated, data-driven alerts.
Final Assessment
Can Senseonics Holdings stock reach $13? The figure represents the mean of six current analyst targets spanning roughly $9 to $18, requiring about a 33% advance from the latest price near $9.80. The path is plausible on the strength of accelerating revenue and pipeline catalysts, but it is far from assured given persistent losses, dilution risk, and intense competition. The unusually wide target range shows that analysts themselves disagree sharply about the outcome, and the stock's next moves will depend most on commercial execution and funding discipline.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SENS in downward trend: price dove below 50-day moving average on November 02, 2026
SENS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 26 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where SENS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The 10-day moving average for SENS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SENS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SENS's RSI Indicator exited the oversold zone, 40 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SENS as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SENS just turned positive on October 28, 2026. Looking at past instances where SENS's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +17.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SENS advanced for three days, in 198 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.029) is normal, around the industry mean (4.142). P/E Ratio (-3.835) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.058) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative glucose monitoring products
Industry MedicalNursingServices
Advertisement